Diversion Control Division, US Department of Justice, Drug Enforcement Administration

ABOUT US > What's New

What's New

May

Patheon API Manufacturing, Inc. (May 12, 2021)

Rosa A. Fuentes, M.D.; Decision and Order (May 11, 2021)

Final Rule: Designation of 3,4-MDP-2-P methyl glycidate (PMK glycidate), 3,4-MDP-2-P methyl glycidic acid (PMK glycidic acid), and alpha-phenylacetoacetamide (APAA) as List I Chemicals (May 10, 2021)

Interim Final Rule: Placement of Serdexmethylphenidate in Schedule IV (May 7, 2021)

Indian Flower LLC (May 7, 2021)

Green Rush Organic Farms Inc. (May 7, 2021)

Melanie Baker, N.P.; Decision and Order (May 5, 2021)

Michele L. Martinho, M.D.; Decision and Order (May 5, 2021)

Emmanuel A. Ayodele, M.D.; Decision and Order (May 5, 2021)

Final Rule: Placement of Four Specific Fentanyl-Related Substances in Schedule I (May 4, 2021)

Cargill, Incorporated (May 4, 2021)

VHG Labs DBA LGC Standards (May 4, 2021)

Wildlife Laboratories, LLC (May 4, 2021)


April

Final Rule: Placement of 10 Specific Fentanyl-Related Substances in Schedule I (April 27, 2021)

60-Day Notice: New Proposed Collection Exempt Chemical Preparations Application (April 26, 2021)

Rhodes Technologies (April 26, 2021)

Exempt Chemical Preparations Under the Controlled Substances Act (PDF) (April 23, 2021)

Rhodes Technologies (April 23, 2021)

Cardinal Health (April 23, 2021)

Lipomed (April 23, 2021)

Research Triangle Institute (April 21, 2021)

Mark A. Wimbley, M.D.; Decision and Order (PDF) (April 21, 2021)

Michael Jones, M.D.; Decision and Order (April 21, 2021)

Javaid A. Perwaiz, M.D.; Decision and Order (April 21, 2021)

Research Triangle Institute (April 21, 2021)

Scottsdale Research Institute (April 21, 2021)

The Pharmacy Place; Order (PDF) (April 21, 2021)

Final Rule: Removal of Samidorphan From Control (April 19, 2021)

Jennifer L. St. Croix, M.D.; Decision and Order (PDF) (April 12, 2021)

Royal Emerald Pharmaceuticals (April 5, 2021)

Brenton D. Goodman, M.D.; Decision and Order (April 2, 2021)

Kendrick E. Duldulao, M.D.; Decision and Order (April 2, 2021)

ThinkPur, LLC (April 1, 2021)

Sharp Clinical Services, Inc. (April 1, 2021)


March

Final Rule: Placement of cyclopentyl fentanyl, isobutyryl fentanyl, para-chloroisobutyryl fentanyl, para-methoxybutyryl fentanyl, and valeryl fentanyl in Schedule I; Correction (March 31, 2021)

Extension of Temporary Placement of 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA and FUB-144 in Schedule I of the Controlled Substances Act (March 31, 2021)

Ester Mark, M.D.; Decision and Order (PDF) (March 31, 2021)

Eric R. Shibley, M.D.; Decision and Order (March 31, 2021)

Roozbeh Badii, M.D.; Decision and Order (March 31, 2021)

Proposed Rule: Designation of Methyl alpha-phenylacetoacetate, a Precursor Chemical Used in the Illicit Manufacture of Phenylacetone, Methamphetamine, and Amphetamine, as a List I Chemical (March 30, 2021)

Proposed Rule: Placement of 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA and FUB-144 in Schedule I (March 30, 2021)

MMJ 95, LLC (March 26, 2021)

Shertech Laboratories, LLC (March 24, 2021)

Medi-Physics Inc. dba GE Healthcare (March 24, 2021)

Perkinelmer, Inc. (March 24, 2021)

Lawrence E. Stewart; Decision and Order (March 22, 2021)

Proposed Rule: Placement of Four Specific Fentanyl-Related Substances in Schedule I (March 18, 2021)

Noramco Coventry, LLC (March 18, 2021)

Cambridge Isotope Lab; Correction (March 16, 2021)

Purisys, LLC (March 16, 2021)

Patheon Pharmaceuticals Inc. (March 9, 2021)

Stepan Company (March 9, 2021)

Groff NA Hemplex LLC (March 9, 2021)

Proposed Rule: Placement of 10 Specific Fentanyl-Related Substances in Schedule I (March 3, 2021)

Final Rule: Placement of Lemborexant in Schedule IV (March 3, 2021)

Stepan Company (March 2, 2021)

Temporary Placement of Brorphine in Schedule I (March 1, 2021)

Cosmic Light LLC (March 1, 2021)

Groff NA Hemplex, LLC (March 1, 2021)

Microgenics Corporation Thermo Fisher Scientific (March 1, 2021)


February

Proposed Rule; Reopening of Comment Period: Suspicious Orders of Controlled Substances (February 25, 2021)

Chattem Chemicals (February 25, 2021)

S&B Pharma, Inc. (February 25, 2021)

Myonex Inc. (February 25, 2021)

AJC Industries, Inc. (February 24, 2021)

GGGYI LLC (February 24, 2021)

Sigma Aldrich Research Biochemicals, Inc. (February 24, 2021)

Livwell Michigan, LLC (February 24, 2021)

Synthcon LLC (February 24, 2021)

Globyz Pharma, LLC (February 24, 2021)

30-Day Notice: Registration for CSA Data-Use Request (February 22, 2021)

Patheon API Manufacturing, Inc. (February 19, 2021)

Milad I. Shaker, M.D.; Decision and Order (February 19, 2021)

Michael W. Carlton, M.D.; Decision and Order (PDF) (February 19, 2021)

Ibrahim Al-Qawaqneh, D.D.S.; Decision and Order (February 19, 2021)

VHG Labs DBA LGC Standards (February 19, 2021)

North Star Holdings California, LLC (February 16, 2021)

Mountain Trading LLC (February 16, 2021)

JW Colorado, LLC (February 16, 2021)

Titan Health LLC (February 16, 2021)

PCI Synthesis (February 16, 2021)

S and B Pharma, Inc. (February 16, 2021)

Noramco Coventry, LLC (February 16, 2021)

Sigma Aldrich Co., LLC (February 16, 2021)

Siegfried USA, LLC (February 16, 2021)

Sterling Pharma USA, LLC (February 5, 2021)

Noramco, Inc. (February 5, 2021)

Mylan Pharmaceuticals Inc. (February 4, 2021)


January 2021

Indigenous Peyote Conservation Initiative (January 28, 2021)

Siemens Healthcare Diagnostics Inc. (January 14, 2021)

IsoSciences, LLC (January 14, 2021)

Cedarburg Pharmaceuticals (January 12, 2021)

Organix, Inc. (January 12, 2021)

Siegfried USA, LLC (January 12, 2021)

Natural Fulfillment LLC (January 12, 2021)

Medi-Physics, Inc. dba GE Healthcare (January 12, 2021)

S&B Pharma LLC dba Norac Pharma (January 12, 2021)

Proposed Rule: Amending Regulations To Require Online Submission of Applications for and Renewals of DEA Registration (PDF) (January 7, 2021)


December 2020

Brian M. Manjarres, M.D.; Decision and Order (Tuesday, December 29, 2020)

Irene G. Gurvits, M.D.; Decision and Order (Tuesday, December 29, 2020)

Annamalai Ashokan, M.D.; Decision and Order (Tuesday, December 29, 2020)

Steven M. Kotsonis, M.D.; Order (Tuesday, December 29, 2020)

Fresenius Kabi USA, LLC (December 22, 2020)

Yourway Transport (December 22, 2020)

Organic Standards Solutions International, LLC (December 22, 2020)

Proposed Rule: Designation of 3,4-MDP-2-P Methyl Glycidate (PMK Glycidate), 3,4-MDP-2-P Methyl Glycidic Acid (PMK Glycidic Acid), and Alpha-Phenylacetoacetamide (APAA) as List I Chemicals (December 21, 2020)

Final Rule: Controls To Enhance the Cultivation of Marihuana for Research in the United States (PDF) (December 18, 2020)

Order With Opportunity for Comment: Exempt Anabolic Steroid Products (December 16, 2020)

Sterling Wisconsin, LLC (December 15, 2020)

Adiramedica LLC (December 15, 2020)

Sterling Pharma USA, LLC (December 11, 2020)

Johnson Matthey, Inc. (December 11, 2020)

King Wong, M.D.; Decision and Order (December 11, 2020)

Zeljko Stjepanovic, M.D.; Decision and Order (December 11, 2020)

Anindita Nandi, M.D.; Decision and Order (December 11, 2020)

Lisa Hofschulz, N.P.; Decision and Order (December 11, 2020)

Poplar Grove Pharmacy Inc.; Decision and Order (December 11, 2020)

Ernesto C. Torres, M.D.; Decision and Order (December 11, 2020)

George Pursley, M.D.; Denial of Application (PDF) (December 11, 2020)

Proposed Rule: Removal of Samidorphan From Control (December 10, 2020)

Johnson Matthey Inc. (December 8, 2020)

Proposed Rule: Partial Filling of Prescriptions for Schedule II Controlled Substances (PDF) (December 4, 2020)

Janssen Pharmaceuticals Inc. (December 4, 2020)

Notice of Intent: Temporary Placement of Brorphine in Schedule I (December 3, 2020)

Janssen Pharmaceuticals Inc. (December 3, 2020)

Final Adjusted Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2020 (December 1, 2020)


November

Established Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2021 (November 30, 2020)

Novitium Pharma LLC (November 27, 2020)

Meridian Medical Technologies (November 27, 2020)

Noramco Inc. (November 27, 2020)

Lyndra Therapeutics (November 27, 2020)

Final Rule: Placement of cyclopentyl fentanyl, isobutyryl fentanyl, para-chloroisobutyryl fentanyl, para-methoxybutyryl fentanyl, and valeryl fentanyl in Schedule I (November 25, 2020)

Johnson Matthey Pharmaceutical Materials Inc. (November 23, 2020)

Lewis Leavitt III, M.D.; Decision and Order (November 19, 2020)

Suntree Pharmacy and Suntree Medical Equipment, LLC; Decision and Order (PDF) (November 19, 2020)

ECO Apothecary, LLC; Decision and Order (November 19, 2020)

Monica Ferguson, F.N.P., R.N.; Decision and Order (November 19, 2020)

Jeffrey M. Wolk, M.D.; Decision and Order (November 19, 2020)

Julie I. Dee, M.D.; Decision and Order (November 19, 2020)

Verne A. Schwager, M.D.; Decision and Order (November 19, 2020)

Jeanne E. Germeil, M.D. Decision and Order (PDF) (November 19, 2020)

Hil Rizvi, M.D.; Decision and Order (November 19, 2020)

Jonathan Rosenfield, M.D.; Decision and Order (November 19, 2020)

Navinta LLC (November 4, 2020)

Cerilliant Corporation (November 4, 2020)

Proposed Rule: Suspicious Orders of Controlled Substances (PDF) (November 2, 2020)

Interim Final Rule: Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment (PDF) (November 2, 2020)

Emergency Disaster Relief
Search for Year Round Pharmaceutical Disposal Locations.
National Prescription Drug Take Back Day. Turn in your unused or expired medication for safe disposal here.
RX Abuse Online

U.S. DEPARTMENT OF JUSTICE  •  DRUG ENFORCEMENT ADMINISTRATION
Diversion Control Division  •  8701 Morrissette Drive  •  Springfield, VA 22152  •  1-800-882-9539

DOJ Legal Policies and Disclaimers    |    DOJ Privacy Policy    |    FOIA    |    Section 508 Accessibility